BioCentury-BayHelix East-West Summit 2022 Details
BioCentury and BayHelix invite you to Register Now to join us at the East-West BioPharma Summit at the Grand Bay Hotel San Francisco, Redwood City, CA on Nov. 14-16, 2022*.
For almost a decade, BioCentury and BayHelix and our partners have brought together a global community of C-suite executives and investors focused on biopharma innovation and cross-border collaboration. But the world has changed: Emerging biopharmas in the U.S., Europe and Asia now face the same dilemma: How do you globalize to deliver innovation to patients and achieve an ROI for investors?
- A handful of biopharma companies will build global operations.
- Most will achieve global economics through partnering and licensing.
- Others will capture a share of the economics by enabling global development and financing.
- And all will require trusted cross-border relationships for success.
Globalizing drug development is imperative for creating medicines that reach all patients, regardless of where they live. That takes investors and company leaders with global vision and strategy, in a rapidly evolving environment.
- David Reese, M.D., EVP of R&D, Amgen
- John Lepore, SVP & Head of Research, GlaxoSmithKline
- Kiran Reddy, Senior Managing Director, Blackstone
- Chris Carpenter, M.D., Ph.D., Executive Partner, Sofinnova Investments
And many more….
*Digital passes also available.
“The healthcare industry has seen a wave of innovation and development since the COVID-19 pandemic. The new era, that comes with uncertainties and macroeconomic headwinds, requires CEOs, entrepreneurs, and all to communicate effectively and embrace innovation. BioCentury and BayHelix put together a high-quality program that really captures the latest industry trends and offers a valuable opportunity to connect with thought leaders in the region. We look forward to continuing to support the BioCentury-BayHelix China Healthcare Summit, as we have in the past, and sharing our insights at the event.”
"The BioCentury & BayHelix China Healthcare Summit has grown from strength to strength over the last eight years. It has become the reference China event for the biopharma community, with an increasingly global audience. As McKinsey, we are proud of our contribution to the Summit as Insights Partner, with our series of reports on “Building Bridges to Innovation”. We look forward to the ninth edition of the event. Given the current context around biotech and the biopharma industry, we expect the event to be once again a great gathering of minds to crystalize trends and shape the journey together."